


Abstract #: Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment

Taylor Weiskittel, Austin Koukol, Caroline Kellinger, Andrey Ugolkov, Chris Seifarth, Hu Li, Devalingam Mahalingam, Leiqing Zhang, Benedito Carneiro, Wafik El- Deiry, Andrew Mazar





Background




Preliminary results of the 1801 Part 3B trial (NCT03678883) showed statistically significant benefits for elraglusib+GnP versus GnP for 1-year survival and mOS in mPDAC (companion abstract: Mahalingam et al.). We investigated plasma levels of cytokines/ chemokines/ soluble cell receptors/growth factors (CCSG) as potential biomarkers of favorable outcomes on elraglusib.



Machine Learning Pipeline and Results



Univariate Pipeline and Results



Cytokine	Elraglusib+GnP			GnP only		
	Cutpoint	P-value	HR	Cutpoint	P-value	HR
CCL3.MIP.1.alpha	483.74	p = 0.017	0.61	486.92	p = 0.061	0.58
CXCL2.Gro.beta.MIP.2.CINC.3	357.86	p = 0.001	1.85	826.65	p = 0.0063	0.41
IL.1.alpha.IL.1F1	16.62	p = 0.042	0.48	18.51	p = 0.082	1.99
IL.18.IL.1F4	153.35	p = 0.0055	0.59	264.98	p = 0.15	0.63
TGF.beta.1	10065.87	p = 0.033	0.67	2638.24	p = 0.075	0.41
TRAIL.R3.TNFRSF10C	4700.09	p = 0.045	0.68	2427.90	p = 0.29	0.69
TRAIL.TNFRSF10	92.18	p = 0.0089	1.62	60.32	p = 0.22	1.56

Pre-dose plasma CCSG are promising predictive biomarkers of elraglusib clinical outcomes.

Future Directions

- Patient predose plasma collection on future trials will be tested for the seven cytokines
- Investigate sequential combinations of univariate CCSGs for optimal patient selection and stratification
- Further optimize multivariate machine learning models for increased accuracy in predicting 1-year OS
- Compare machine learning and sequential univariate stratification

Oral (Abstract 4006): Mahalingam et al.
Preliminary results from 1801 part 3B elraglusib in combination with GnP versus GnP with previously untreated mPDAC.
Session: **Saturday, May 31, 2025, 3:00 PM-6:00 PM CDT. Hall D1.**